REGENXBIO (RGNX) Q2 FY26 earnings call

REGENXBIO achieved significant late-stage pipeline milestones for its gene therapies in Duchenne, MPS II, and retinal diseases, including completing enrollment for RGX202 and aligning with the FDA for RGX121 resubmission. The company substantially strengthened its financial position with over $200 million in new capital, extending its cash runway into Q4 2027, enabling continued investment in strategic priorities and commercial readiness.